Marshall Wace, LLP Pro Phase Labs, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.15 - $9.78 $291,920 - $399,297	-40,828 Reduced 78.39%	11,255 $81,000
Q1 2023 May 15, 2023	SELL	$6.62 - $9.57 $245,237 - $354,520	-37,045 Reduced 41.56%	52,083 $396,000
Q4 2022 Feb 14, 2023	BUY	$8.78 - $12.47 $26,647 - $37,846	3,035 Added 3.53%	89,128 $858,000
Q3 2022 Nov 14, 2022	BUY	$8.96 - $14.7 $456,700 - $749,273	50,971 Added 145.13%	86,093 $971,000
Q2 2022 Aug 15, 2022	BUY	$6.52 - $13.24 $228,995 - $465,015	35,122 New	35,122 $446,000
Q4 2021 Feb 14, 2022	SELL	$5.13 - $7.89 $116,969 - $179,899	-22,801 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.89 - $7.82 $111,496 - $178,303	22,801 New	22,801 $119,000
Q2 2021 Aug 13, 2021	SELL	$4.61 - $6.83 $233,957 - $346,622	-50,750 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.19 - $16.0 $314,142 - $812,000	50,750 New	50,750 $375,000

1.71M

Ticker PRPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 16,024,400
Market Cap $10.1M
Description
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.